A Caelyx helye a petefészekrák másodvonalbeli kezelésében

Pulay Tamás, Csömör Sándor, Faluhelyi Zsolt, Hernádi Zoltán, Krommer Károly, Mayer Árpád, Szánthó András, Szántó István, Thurzó László

Research output: Contribution to journalArticle

3 Citations (Scopus)


The authors published their own experiences and results of Caelyx treatment based on 40 ovarian cancer patients treated in 9 different institutions. Patients had been treated with platinum based or platinum-taxol combination chemoterapy. Their average age was 57.2 years (35-80). The average time to progression was 3.8 months (1-8). The effects of the therapy were assessed on 36 patients and the results were 3 CR, 8 PR, 7 SD and 18 PD. Summarised the Caelyx therapy caused improvement in 30.55% of the patients and stabilisation in 19.44%. Supportive therapy was needed in 8 cases.

Original languageHungarian
Pages (from-to)97-99
Number of pages3
JournalMagyar onkologia
Issue number1
Publication statusPublished - Jan 1 2004

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tamás, P., Sándor, C., Zsolt, F., Zoltán, H., Károly, K., Árpád, M., András, S., István, S., & László, T. (2004). A Caelyx helye a petefészekrák másodvonalbeli kezelésében. Magyar onkologia, 48(1), 97-99.